We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Assays Using ddPCR Quantify DNA Fragments

By LabMedica International staff writers
Posted on 14 May 2018
Optimized droplet digital polymerase chain reaction (ddPCR) assays have been developed that quantify short and long DNA fragments. More...
These assays have been used to analyze plasma cell-free (cfDNA) fragment size distribution in human blood.

Circulating cell-free genome in human body fluids is being utilized as a source of genetic material for noninvasive screening, diagnostic and prognostic tests in clinical practice. Plasma cfDNA fragment size distribution provides important information required for diagnostic assay development.

Doctors at the University of Nebraska Medical Center (Omaha, NE, USA) and their colleagues collected blood samples from certified healthy donors and first trimester pregnant donors. Plasma was separated immediately after blood draw by two centrifugation steps. Exosomes were isolated from cell-free plasma using Invitrogen Total Exosome isolation from plasma kit.

Plasma and plasma exosome DNA was extracted using QIAamp Circulating Nucleic Acid Kit. Bio-Rad Automated Droplet Generator was used to generate droplets and thermal cycling was done using Bio-Rad C1000 Touch Thermal cycler. DNA extracted from blood plasma was analyzed using Agilent Bioanalyzer 2100 instrument and Agilent DNA High Sensitivity Kit.

The team developed and optimized four different EvaGreen chemistry based ddPCR assays to amplify four different amplicons with different sizes from human β-actin gene in order to accurately quantify cfDNA with different sizes in human blood plasma. They used concentrated human blood plasma cfDNA as genetic material for the development of these assays. These assays amplify 76, 135, 490 and 905 bp amplicons from human β-actin gene.

The study showed that cfDNA in human blood plasma has two localizations. Blood plasma exosomes are one such localization harboring cfDNA of mostly small fragments. About 72% of cfDNA localized in exosomes are small DNA fragments, less than 490 bp. Blood plasma apoptotic bodies and nucleuses are the other localizations where cfDNA is present. DNA concentration in plasma pellet was seven-fold higher than plasma cfDNA.

The authors concluded that non-pregnant plasma cell-free and exosome DNA share a unique fragment distribution pattern, which is different from pregnant donor plasma and exosome DNA fragment distribution indicating the effect of physiological status on cfDNA fragment size distribution. Fragment distribution pattern for plasma pellet that includes apoptotic bodies and nuclear DNA was greatly different from plasma cell-free and exosome DNA. The study was published online on April 12, 2018, in the journal Clinica Chimica Acta.

Related Links:
University of Nebraska Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers compared Huntington’s disease biomarkers in CSF and blood with clinical assessments and brain imaging to better understand changes before clinical onset (Image Credit: Adobe Stock)

Blood and Spinal Fluid Biomarker May Help Track Early Huntington’s Disease

Huntington’s disease is a genetic disorder caused by a mutation in the HTT gene that progressively affects movement, cognition, behavior, and independence. Although mutation carriers can be identified... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.